Atrial Fibrillation
Conditions
Brief summary
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e. with a therapeutic indication for dual or triple antithrombotic therapy) and to analyze the outcomes of therapeutic decisions, focusing on mortality, hemorrhagic events, and ischemic events,
Detailed description
The combination of warfarin, aspirin, and clopidogrel represented the standard antithrombotic therapeutic strategy for patients with atrial fibrillation and suffering from acute coronary syndrome and/or undergoing percutaneous coronary intervention. Current guidelines and clinical practice guides suggest the use of triple or dual antithrombotic therapy after a careful evaluation of the patient's hemorrhagic and thrombotic profile, without however providing indications with recommendation class I. It is not known what treatment regimens are prescribed in the real world, i.e. how clinicians behave in the absence of clear guidelines. This observational study involves patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e. with a therapeutic indication for dual or triple antithrombotic therapy), to describe the real-world prescription model used in clinical practice and to analyze the results of therapeutic choices in terms of mortality, hemorrhagic and ischemic events. Patients are enrolled within 7 days from percutaneous coronary intervention during their hospitalization period. During the enrolment visit (i.e. baseline, T0), all patients undergo a detailed assessment of their medical history related to the recent hospitalization, laboratory blood analysis, and data related to their cardiovascular risk factors. Follow-up visits will be performed at three months (T3) and twelve months (T12). During the follow-up visit, any ischemic/bleeding events, therapeutic changes, and laboratory blood analysis will be recorded.
Interventions
OTHERObservation
Observation of mortality, haemorrhagic and ischemic events in the studied population
Sponsors
Società Italiana Cardiologia Ospedalità Accreditata (SICOA)
Istituti Clinici Scientifici Maugeri SpA
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with non valvular atrial fibrillation with direct oral anticoagulants therapy * Patient on antiplatelet therapy (acetylsalicylic acid and/or inhibitor of the P2Y12 platelet receptor) * Patient hospitalized for percutaneous coronary intervention in the previous 7 days * Age ≥18 years * Estimated life expectancy ≥ 12 months * Ability to give informed consent
Exclusion criteria
* Patients who have contraindications to direct oral anticoagulants therapy * Patients who are indicated for direct oral anticoagulants therapy for reasons other than non valvular atrial fibrillation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding | 3 months | Incidence of major bleeding and clinically relevant non major bleeding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 3 months | Cardiovascular events, death |
Countries
Italy
Outcome results
None listed